PCSK9 inhibition for patients with and without prior coronary revascularization: Potential additional benefit of a novel therapeutic agent

被引：2
|
作者：
Navarese, Eliano P. [1 ,2 ,3 ,4 ]
Raggi, Paolo [4 ,5 ]
机构：
[1] INOVA Heart & Vasc Inst, Fairfax, VA USA
[2] Mater Dei Hosp, Cardiovasc Res Ctr, Intervent Cardiol & Cardiovasc Res, Bari, Italy
[3] SIRIO Med Network, Milan, Italy
[4] Mazankowski Alberta Heart Inst, 8440 112 St,5A9-014, Edmonton, AB T6G 2B7, Canada
[5] Univ Alberta, Dept Med, Edmonton, AB, Canada
来源：
ATHEROSCLEROSIS | 2018年 / 277卷
关键词：
PCSK9; Lipid lowering; Lipoproteins; Low density lipoprotein cholesterol; LIPOPROTEIN(A);
D O I：
10.1016/j.atherosclerosis.2018.07.038
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：177 / 178
页数：2
相关论文
共 29 条
  • [1] PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease
    Lee, Ji Soo
    Mukhopadhyay, Partha
    Matyas, Csaba
    Trojnar, Eszter
    Paloczi, Janos
    Yang, Yuan Ru
    Blank, Brandon A.
    Savage, Cody
    Sorokin, Alexander V.
    Mehta, Nehal N.
    Vendruscolo, Janaina C. M.
    Koob, George F.
    Vendruscolo, Leandro F.
    Pacher, Pal
    Lohoff, Falk W.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [2] PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease
    Ji Soo Lee
    Partha Mukhopadhyay
    Csaba Matyas
    Eszter Trojnar
    Janos Paloczi
    Yuan Ru Yang
    Brandon A. Blank
    Cody Savage
    Alexander V. Sorokin
    Nehal N. Mehta
    Janaina C. M. Vendruscolo
    George F. Koob
    Leandro F. Vendruscolo
    Pal Pacher
    Falk W. Lohoff
    Scientific Reports, 9
  • [3] PCSK9 INHIBITION AS A NOVEL THERAPEUTIC TARGET FOR ALCOHOLIC LIVER DISEASE
    Lee, J.
    Mukhopadhyay, P.
    Matyas, C.
    Trojnar, E.
    Paloczi, J.
    Yang, Y. R.
    Blank, B. A.
    Savage, C.
    Sorokin, A. V.
    Mehta, N. N.
    Vendruscolo, J. C. M.
    Koob, G. F.
    Vendruscolo, L. F.
    Pacher, P.
    Lohoff, F. W.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2020, 44 : 45 - 45
  • [4] Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
    Schwartz, Gregory G.
    Szarek, Michael
    Bittner, Vera A.
    Diaz, Rafael
    Goodman, Shaun G.
    Jukema, J. Wouter
    Landmesser, Ulf
    Lopez-Jaramillo, Patricio
    Manvelian, Garen
    Pordy, Robert
    Scemama, Michel
    Sinnaeve, Peter R.
    White, Harvey D.
    Steg, Ph Gabriel
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 78 (05) : 421 - 433
  • [5] Realizing the Potential of PCSK9 Inhibition A Novel Oral Macrocyclic Peptide on the Horizon
    Chapman, M. John
    Packard, Chris J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (16) : 1565 - 1568
  • [6] Effect of PCSK9 inhibition on platelet reactivity in coronary artery disease patients
    Galli, Lukas
    Ondracek, Anna
    Seidl, Veronika
    Hofbauer, Thomas
    Zedan, Yasmin
    Schrutka, Lore
    Krychtiuk, Konstantin
    Lang, Irene M.
    Speidl, Walter
    Distelmaier, Klaus
    WIENER KLINISCHE WOCHENSCHRIFT, 2019, 131 : 372 - 373
  • [7] Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease
    Kaasenbrood, Lotte
    Ray, Kausik K.
    Boekholdt, S. Matthijs
    Smulders, Yvo M.
    LaRosa, John C.
    Kastelein, John J. P.
    van der Graaf, Yolanda
    Dorresteijn, Johannes A. N.
    Visseren, Frank L. J.
    HEART, 2018, 104 (20) : 1699 - 1705
  • [8] Inhibition of hepatic PCSK9 as a novel therapeutic target ameliorates metabolic steatohepatitis in mice
    Mijiti, Tuoluonayi
    Chen, Xiaocui
    Ma, Xiang
    Ma, Yitong
    Ma, Xiumin
    Chen, Bangdang
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 143
  • [9] Lower rate of ischemic events with PCSK9 inhibition in patients with atherosclerotic cardiovascular disease but without prior ischemic events
    Bhatt, D.
    Khan, I
    Koumas, A.
    Filardi, P. P.
    Fernandez, J. T.
    Marx, N.
    Cabezas, M. C.
    Andrade, K.
    Potukuchi, P.
    Pereira, C.
    Garon, G.
    Tokgozoglu, L.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [10] Lipoprotein(a) and Benefit of PCSK9 Inhibition in Emergency Complex Higher-risk and Indicated Patients
    Jin, Zhi-li
    He, Tao
    Peng, Li
    Wu, Xiao-yan
    Fan, Di
    Chen, Ming
    Fan, Yong-zhen
    Guo, Yuan-lin
    Lu, Zhi-bing
    Wang, Hai-rong
    CURRENT MEDICAL SCIENCE, 2023, 43 (06) : 1206 - 1212
123